RU2008110504A - Способы лечения диабета и снижения массы тела - Google Patents
Способы лечения диабета и снижения массы тела Download PDFInfo
- Publication number
- RU2008110504A RU2008110504A RU2008110504/15A RU2008110504A RU2008110504A RU 2008110504 A RU2008110504 A RU 2008110504A RU 2008110504/15 A RU2008110504/15 A RU 2008110504/15A RU 2008110504 A RU2008110504 A RU 2008110504A RU 2008110504 A RU2008110504 A RU 2008110504A
- Authority
- RU
- Russia
- Prior art keywords
- exendin
- plasma
- analog
- level
- concentration
- Prior art date
Links
- 230000037396 body weight Effects 0.000 title claims abstract 6
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 claims abstract 19
- 230000036470 plasma concentration Effects 0.000 claims abstract 6
- 108010011459 Exenatide Proteins 0.000 claims abstract 5
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims abstract 5
- 229960001519 exenatide Drugs 0.000 claims abstract 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract 4
- 239000008103 glucose Substances 0.000 claims abstract 4
- 230000004580 weight loss Effects 0.000 claims abstract 4
- 210000002784 stomach Anatomy 0.000 claims abstract 2
- 239000013585 weight reducing agent Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Peptides Or Proteins (AREA)
- Feed For Specific Animals (AREA)
Abstract
1. Способ снижения уровня HbA1C и массы тела у индивида, в случае необходимости предусматривающий введение индивиду эксендина или аналога агониста эксендина в количестве, поддерживающем содержание эксендина или аналога агониста эксендина на уровне минимальной концентрации в плазме, составляющей по меньшей мере 170 пг/мл, в течение по меньшей мере 1 месяца. ! 2. Способ по п.1, где эксендин представляет собой эксендин-4. ! 3. Способ по п.1, где снижение уровня HbA1c составляет по меньшей мере 1,5%. ! 4. Способ по п.1, где уровень HbA1c снижают до уровня менее 7,0%. ! 5. Способ по п.1, где уровень HbA1c снижают до уровня менее 6,5%. ! 6. Способ по п.1, где снижение массы составляет по меньшей мере 2 кг. ! 7. Способ по п.1, где минимальная концентрация эксендина или аналога агониста эксендина в плазме составляет от 200 до 600 пг/мл. ! 8. Способ по п.1, где минимальная концентрация в плазме приводит к средней концентрации эксендина или аналога агониста эксендина в плазме, составляющей от 170 до 600 пг/мл. ! 9. Способ снижения уровня глюкозы в плазме натощак и массы тела у индивида, в случае необходимости предусматривающий введение индивиду эксендина или аналога агониста эксендина в количестве, поддерживающем содержание эксендина или аналога агониста эксендина на уровне минимальной концентрации в плазме, составляющей по меньшей мере 170 пг/мл, в течение по меньшей мере 1 месяца. ! 10. Способ по п.9, где эксендин представляет собой эксендин-4. ! 11. Способ по п.9, где уровень глюкозы в плазме натощак снижают до уровня менее 140 мг/дл. ! 12. Способ по п.9, где снижение массы составляет по меньшей мере 2 кг. ! 13. Способ по п.9, где минимальная концентрация эксендина или аналога агониста эксенд�
Claims (20)
1. Способ снижения уровня HbA1C и массы тела у индивида, в случае необходимости предусматривающий введение индивиду эксендина или аналога агониста эксендина в количестве, поддерживающем содержание эксендина или аналога агониста эксендина на уровне минимальной концентрации в плазме, составляющей по меньшей мере 170 пг/мл, в течение по меньшей мере 1 месяца.
2. Способ по п.1, где эксендин представляет собой эксендин-4.
3. Способ по п.1, где снижение уровня HbA1c составляет по меньшей мере 1,5%.
4. Способ по п.1, где уровень HbA1c снижают до уровня менее 7,0%.
5. Способ по п.1, где уровень HbA1c снижают до уровня менее 6,5%.
6. Способ по п.1, где снижение массы составляет по меньшей мере 2 кг.
7. Способ по п.1, где минимальная концентрация эксендина или аналога агониста эксендина в плазме составляет от 200 до 600 пг/мл.
8. Способ по п.1, где минимальная концентрация в плазме приводит к средней концентрации эксендина или аналога агониста эксендина в плазме, составляющей от 170 до 600 пг/мл.
9. Способ снижения уровня глюкозы в плазме натощак и массы тела у индивида, в случае необходимости предусматривающий введение индивиду эксендина или аналога агониста эксендина в количестве, поддерживающем содержание эксендина или аналога агониста эксендина на уровне минимальной концентрации в плазме, составляющей по меньшей мере 170 пг/мл, в течение по меньшей мере 1 месяца.
10. Способ по п.9, где эксендин представляет собой эксендин-4.
11. Способ по п.9, где уровень глюкозы в плазме натощак снижают до уровня менее 140 мг/дл.
12. Способ по п.9, где снижение массы составляет по меньшей мере 2 кг.
13. Способ по п.9, где минимальная концентрация эксендина или аналога агониста эксендина в плазме составляет от 200 до 600 пг/мл.
14. Способ по п.9, где минимальная концентрация в плазме приводит к средней концентрации эксендина или аналога агониста эксендина в плазме, составляющей от 170 до 600 пг/мл.
15. Способ снижения массы тела индивида, в случае необходимости предусматривающий введение индивиду эксендина или аналога агониста эксендина в количестве, поддерживающем содержание эксендина или аналога агониста эксендина на уровне минимальной концентрации в плазме, составляющей по меньшей мере 170 пг/мл, в течение по меньшей мере 1 месяца.
16. Способ по п.15, где эксендин представляет собой эксендин-4.
17. Способ по п.15, где снижение массы составляет по меньшей мере 2 кг.
18. Способ по п.15, где снижение массы составляет по меньшей мере 4 кг.
19. Способ по п.15, где минимальная концентрация эксендина или аналога агониста эксендина в плазме составляет от 200 до 600 пг/мл.
20. Способ по п.15, где минимальная концентрация в плазме приводит к средней концентрации эксендина или аналога агониста эксендина в плазме, составляющей от 200 до 600 пг/мл.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70960405P | 2005-08-19 | 2005-08-19 | |
| US60/709,604 | 2005-08-19 | ||
| US77921606P | 2006-03-03 | 2006-03-03 | |
| US60/779,216 | 2006-03-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008110504A true RU2008110504A (ru) | 2009-09-27 |
| RU2421237C2 RU2421237C2 (ru) | 2011-06-20 |
Family
ID=37772212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008110504/15A RU2421237C2 (ru) | 2005-08-19 | 2006-08-18 | Способы лечения диабета и снижения массы тела |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US20090239796A1 (ru) |
| EP (3) | EP3524261B1 (ru) |
| JP (2) | JP5693817B2 (ru) |
| KR (1) | KR101059279B1 (ru) |
| CN (1) | CN105056211A (ru) |
| AU (2) | AU2006283517B2 (ru) |
| BR (1) | BRPI0615358B8 (ru) |
| CA (1) | CA2619426C (ru) |
| CY (1) | CY1122010T1 (ru) |
| DK (3) | DK3524261T5 (ru) |
| ES (3) | ES2526463T3 (ru) |
| FI (1) | FI3524261T3 (ru) |
| HR (1) | HRP20150186T1 (ru) |
| HU (2) | HUE045165T2 (ru) |
| IL (2) | IL189607A (ru) |
| LT (2) | LT2347762T (ru) |
| MX (1) | MX2008002370A (ru) |
| NZ (2) | NZ566763A (ru) |
| PL (3) | PL3524261T3 (ru) |
| PT (3) | PT2347762T (ru) |
| RS (1) | RS53814B1 (ru) |
| RU (1) | RU2421237C2 (ru) |
| SG (1) | SG184730A1 (ru) |
| SI (3) | SI1971362T1 (ru) |
| WO (1) | WO2007024700A2 (ru) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| JP4343948B2 (ja) | 2003-04-29 | 2009-10-14 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少に影響を及ぼすための組成物 |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| MX2008002370A (es) | 2005-08-19 | 2008-04-29 | Amylin Pharmaceuticals Inc | Exendina para tratar la diabetes y reducir el peso del cuerpo. |
| CN101453982B (zh) | 2006-05-30 | 2011-05-04 | 精达制药公司 | 两件式内部通道渗透递送系统流动调节器 |
| NZ593017A (en) | 2006-08-09 | 2011-08-26 | Intarcia Therapeutics Inc | Piston assembly for positioning lumen in an osmotic delivery system having groove to retain elastomeric O-ring |
| RU2440097C2 (ru) | 2007-04-23 | 2012-01-20 | Интарсия Терапьютикс, Инк. | Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления |
| JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
| WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| WO2009143285A2 (en) | 2008-05-21 | 2009-11-26 | Amylin Pharmaceuticals, Inc. | Exendins to lower cholestrol and triglycerides |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| PL2341905T5 (pl) | 2008-09-04 | 2024-01-15 | Amylin Pharmaceuticals, Llc | Preparaty o przedłużonym uwalnianiu z wykorzystaniem niewodnych nośników |
| DK2349324T3 (en) | 2008-10-17 | 2017-12-11 | Sanofi Aventis Deutschland | COMBINATION OF AN INSULIN AND A GLP-1 AGONIST |
| US20120231022A1 (en) | 2009-05-28 | 2012-09-13 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for sleep enhancement |
| AU2010279575B2 (en) | 2009-08-03 | 2016-05-05 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| SMT201700583T1 (it) | 2009-09-28 | 2018-01-11 | Intarcia Therapeutics Inc | Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario |
| US20120294855A1 (en) | 2009-11-03 | 2012-11-22 | Eli Lilly & Company | Glp-1 receptor agonist compounds for obstructive sleep apnea |
| ES2965209T3 (es) | 2009-11-13 | 2024-04-11 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina |
| KR101836070B1 (ko) | 2009-11-13 | 2018-03-09 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물 |
| US8759284B2 (en) | 2009-12-24 | 2014-06-24 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| EP2523557B1 (en) | 2010-01-11 | 2019-09-25 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
| EP2389945A1 (en) * | 2010-05-28 | 2011-11-30 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising AVE0010 and insulin glargine |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| WO2012054817A1 (en) * | 2010-10-22 | 2012-04-26 | Mitokine Bioscience, Llc | Delaying and/ or treating hyperglycemia, including diabetes, with poly(alkyl carboxylic acids) |
| RS56998B1 (sr) | 2010-12-16 | 2018-05-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| WO2012101292A1 (es) | 2011-01-25 | 2012-08-02 | Viviabiotech, S.L. | Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| MY161450A (en) | 2011-04-12 | 2017-04-14 | Novo Nordisk As | Double-acylated glp-1 derivatives |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
| ES2550357T3 (es) | 2011-08-29 | 2015-11-06 | Sanofi-Aventis Deutschland Gmbh | Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| US10865419B2 (en) * | 2011-10-24 | 2020-12-15 | The Trustees Of The University Of Pennsylvania | Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| LT2827885T (lt) | 2012-03-22 | 2018-10-10 | Novo Nordisk A/S | Glp-1 peptidų kompozicijos ir jų gavimas |
| EP4629257A3 (en) | 2012-06-06 | 2025-12-10 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SI2934568T1 (en) | 2012-12-21 | 2018-03-30 | Sanofi | Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon |
| US20160039877A1 (en) | 2013-03-15 | 2016-02-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| JP6672140B2 (ja) | 2013-05-02 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１化合物の経口投薬 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TWI668010B (zh) * | 2014-05-07 | 2019-08-11 | 丹麥商諾佛 儂迪克股份有限公司 | 使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| RU2573933C1 (ru) * | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| CN107106499B (zh) | 2014-11-02 | 2021-09-17 | 纳诺精密医疗有限公司 | 用于延长释放治疗剂的可植入医药装置 |
| HRP20230470T1 (hr) | 2014-12-12 | 2023-07-21 | Sanofi-Aventis Deutschland Gmbh | Formulacija fiksnog omjera inzulin glargin/liksisenatid |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| US10894054B2 (en) | 2015-04-07 | 2021-01-19 | Intercept Pharmaceuticals, Inc. | FXR agonist compositions for combination therapy |
| HRP20211768T1 (hr) | 2015-05-22 | 2022-02-18 | The Board Of Trustees Of The Leland Stanford Junior University | Liječenje postbarijatrijske hipoglikemije s antagonistima glp-1 |
| KR101661332B1 (ko) * | 2015-05-28 | 2016-09-29 | (의료)길의료재단 | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 |
| JP6993235B2 (ja) | 2015-06-03 | 2022-01-13 | インターシア セラピューティクス，インコーポレイティド | インプラントの設置及び撤去システム |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| US20170098040A1 (en) * | 2015-10-06 | 2017-04-06 | Scale Down | Weight management system and method |
| WO2017152014A1 (en) | 2016-03-04 | 2017-09-08 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
| US11207415B2 (en) | 2016-04-15 | 2021-12-28 | Syracuse University | Peptide drug improvement using vitamin B12 and haptocorrin binding substrate conjugates |
| EP3733694A1 (en) | 2016-05-16 | 2020-11-04 | Intarcia Therapeutics, Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| WO2018057977A1 (en) | 2016-09-23 | 2018-03-29 | Delpor, Inc. | Stable compositions for incretin mimetic compounds |
| EP4591853A1 (en) | 2016-11-21 | 2025-07-30 | Amylyx Pharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
| JP7286542B2 (ja) | 2017-01-03 | 2023-06-05 | インターシア セラピューティクス，インコーポレイティド | Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法 |
| DK3570874T3 (da) | 2017-01-17 | 2023-04-11 | Univ Wayne State | Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder |
| JP2020510028A (ja) | 2017-03-08 | 2020-04-02 | インターシア セラピューティクス，インコーポレイティド | 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法 |
| EP3609577B1 (en) * | 2017-04-14 | 2024-09-11 | University of Massachusetts | Brown fat-selective adipokines |
| JP7169673B2 (ja) | 2017-05-11 | 2022-11-11 | シェンツェン ハイタイド バイオファーマシューティカル，エルティーディー． | 急性膵炎の処置におけるペプチド化合物の使用 |
| MX2020007598A (es) | 2018-02-02 | 2020-09-03 | Novo Nordisk As | Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante. |
| WO2019240755A1 (en) * | 2018-06-11 | 2019-12-19 | Wellesley Pharmaceuticals, Llc | Pharmaceutical compositions and methods for weight loss |
| KR20210077693A (ko) * | 2018-10-12 | 2021-06-25 | 미라키 이노베이션 씽크 탱크 엘엘씨 | 지방 감소용 냉각 용액 |
| KR102786259B1 (ko) * | 2018-10-30 | 2025-03-26 | 지아닝 리우 | Glp-1 수용체 작용제 활성을 갖는 glp-1 폴리펩티드 및 그의 용도 |
| CA3180674A1 (en) | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
| KR102556528B1 (ko) * | 2020-12-08 | 2023-07-17 | 경희대학교 산학협력단 | 대사성 질환 예방, 개선 또는 치료용 조성물 |
| CN119770624B (zh) * | 2025-03-13 | 2025-07-08 | 上海水大技术转移有限公司 | 一种抗冻蛋白在减肥降糖中的应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US386998A (en) | 1888-07-31 | Boiler | ||
| US3490597A (en) | 1966-07-22 | 1970-01-20 | Purolator Products Inc | Cover plate for spin-on-filter |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5445781A (en) | 1991-08-28 | 1995-08-29 | Centro Sviluppo Settori Impiego S.R.L. | Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow |
| US5509305A (en) | 1992-02-12 | 1996-04-23 | Daniel Industries, Inc. | Closely coupled, dual turbine volumetric flow meter |
| US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| GB2282891B (en) | 1993-10-13 | 1997-09-03 | Tokai Rika Co Ltd | Acceleration detecting apparatus |
| US5650173A (en) | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| CA2474701C (en) | 1993-11-19 | 2009-01-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradeable microparticles containing a biologically active agent |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| WO1998005351A1 (en) | 1996-08-08 | 1998-02-12 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
| DE69831673C5 (de) | 1997-01-07 | 2015-01-22 | Amylin Pharmaceuticals, Llc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| EP1512395A1 (en) | 1997-07-18 | 2005-03-09 | Azopax Therapeutics LLC | Biodegradable macromers for the controlled release of biologically active substances |
| DK1140145T4 (da) * | 1999-01-14 | 2019-07-22 | Amylin Pharmaceuticals Llc | Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf |
| US20030087820A1 (en) | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
| PT1143989E (pt) | 1999-01-14 | 2007-03-30 | Amylin Pharmaceuticals Inc | Exendinas para supressão de glucagon |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| WO2000066629A1 (en) * | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6162260A (en) | 1999-05-24 | 2000-12-19 | Novo Nordisk Biochem North America, Inc. | Single-bath biopreparation and dyeing of textiles |
| DK1246638T4 (da) | 2000-01-10 | 2014-09-22 | Amylin Pharmaceuticals Llc | Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi |
| US6602997B2 (en) | 2000-04-27 | 2003-08-05 | Shin-Etsu Bio, Inc. | Whole cell and cell-debris polysaccharide |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| US6479065B2 (en) | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
| AU2002239384B2 (en) | 2000-12-13 | 2007-01-11 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| US6819912B2 (en) | 2001-11-05 | 2004-11-16 | Freescale Semiconductor, Inc. | Variable frequency switching amplifier and method therefor |
| US7092459B2 (en) | 2001-11-08 | 2006-08-15 | Qualcomm, Incorporated | Frequency tracking using pilot and non-pilot symbols |
| GB0206792D0 (en) | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
| AU2003284028B2 (en) | 2002-10-17 | 2007-05-10 | Alkermes, Inc. | Sustained release profile modification |
| AU2003277446A1 (en) | 2002-10-17 | 2004-05-04 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
| US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
| WO2005040195A2 (en) | 2003-10-24 | 2005-05-06 | Azopax Therapeutics Llc | Formulation of exendins |
| WO2005041873A2 (en) | 2003-10-24 | 2005-05-12 | Azopax Therapeutics Llc | Formulation of exendin-4 |
| CA2550695A1 (en) | 2003-12-16 | 2005-06-30 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Glp-1 pharmaceutical compositions |
| US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
| ES2375802T3 (es) * | 2004-04-15 | 2012-03-06 | Alkermes Pharma Ireland Limited | Dispositivo de liberación sostenida a base de pol�?mero. |
| NZ551196A (en) | 2004-05-14 | 2010-08-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
| CA2566354C (en) | 2004-05-28 | 2016-01-12 | Oryxe | A mixture for transdermal delivery of low and high molecular weight compounds |
| SI1786400T1 (sl) | 2004-08-12 | 2009-08-31 | Quest Pharmaceutical Services | Farmacevtski sestavki za dajanje biološko aktivnih spojin z nadzorovanim sproščanjem |
| US20060034889A1 (en) | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
| US7442682B2 (en) | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| MX2008002370A (es) | 2005-08-19 | 2008-04-29 | Amylin Pharmaceuticals Inc | Exendina para tratar la diabetes y reducir el peso del cuerpo. |
| WO2007022518A2 (en) | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
| US7512298B2 (en) | 2006-12-01 | 2009-03-31 | 3M Innovative Properties Company | Optical sensing methods |
| IT1402944B1 (it) | 2010-12-15 | 2013-09-27 | Sarong Spa | Capsula per bevande e relativa macchina per utilizzare detta capsula |
| US11638099B2 (en) | 2011-12-23 | 2023-04-25 | Shenzhen Shokz Co., Ltd. | Bone conduction speaker and compound vibration device thereof |
| JP6226510B2 (ja) | 2012-01-27 | 2017-11-08 | キヤノン株式会社 | 画像処理システム、処理方法及びプログラム |
| ITMI20130325A1 (it) | 2013-03-05 | 2014-09-06 | Telecom Italia Spa | Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente |
| US9816387B2 (en) | 2014-09-09 | 2017-11-14 | United Technologies Corporation | Attachment faces for clamped turbine stator of a gas turbine engine |
| CA2914090C (en) | 2015-03-31 | 2023-08-01 | Allen-Vanguard Corporation | Frequency and time domain streaming receiver |
| US9714199B2 (en) | 2015-09-17 | 2017-07-25 | I P Creations Limited | Concealed amalgamated explosive neutralizer and method of manufacture |
-
2006
- 2006-08-18 MX MX2008002370A patent/MX2008002370A/es active IP Right Grant
- 2006-08-18 SI SI200631895T patent/SI1971362T1/sl unknown
- 2006-08-18 LT LTEP10016112.4T patent/LT2347762T/lt unknown
- 2006-08-18 WO PCT/US2006/032354 patent/WO2007024700A2/en not_active Ceased
- 2006-08-18 PT PT10016112T patent/PT2347762T/pt unknown
- 2006-08-18 EP EP19163698.4A patent/EP3524261B1/en active Active
- 2006-08-18 PL PL19163698.4T patent/PL3524261T3/pl unknown
- 2006-08-18 BR BRPI0615358A patent/BRPI0615358B8/pt active IP Right Grant
- 2006-08-18 HR HRP20150186TT patent/HRP20150186T1/hr unknown
- 2006-08-18 SG SG2012066304A patent/SG184730A1/en unknown
- 2006-08-18 ES ES06801867.0T patent/ES2526463T3/es active Active
- 2006-08-18 EP EP06801867.0A patent/EP1971362B1/en not_active Revoked
- 2006-08-18 DK DK19163698.4T patent/DK3524261T5/da active
- 2006-08-18 AU AU2006283517A patent/AU2006283517B2/en active Active
- 2006-08-18 HU HUE10016112A patent/HUE045165T2/hu unknown
- 2006-08-18 DK DK10016112.4T patent/DK2347762T3/da active
- 2006-08-18 ES ES19163698T patent/ES2968190T3/es active Active
- 2006-08-18 NZ NZ566763A patent/NZ566763A/en unknown
- 2006-08-18 LT LTEP19163698.4T patent/LT3524261T/lt unknown
- 2006-08-18 HU HUE19163698A patent/HUE064811T2/hu unknown
- 2006-08-18 PT PT68018670T patent/PT1971362E/pt unknown
- 2006-08-18 US US12/064,216 patent/US20090239796A1/en not_active Abandoned
- 2006-08-18 DK DK06801867.0T patent/DK1971362T3/en active
- 2006-08-18 KR KR1020087006560A patent/KR101059279B1/ko active Active
- 2006-08-18 SI SI200632434T patent/SI3524261T1/sl unknown
- 2006-08-18 JP JP2008527170A patent/JP5693817B2/ja active Active
- 2006-08-18 RU RU2008110504/15A patent/RU2421237C2/ru active
- 2006-08-18 FI FIEP19163698.4T patent/FI3524261T3/fi active
- 2006-08-18 PL PL06801867T patent/PL1971362T3/pl unknown
- 2006-08-18 RS RS20150068A patent/RS53814B1/sr unknown
- 2006-08-18 CN CN201510543460.3A patent/CN105056211A/zh active Pending
- 2006-08-18 EP EP10016112.4A patent/EP2347762B1/en not_active Revoked
- 2006-08-18 CA CA2619426A patent/CA2619426C/en active Active
- 2006-08-18 PT PT191636984T patent/PT3524261T/pt unknown
- 2006-08-18 NZ NZ593461A patent/NZ593461A/xx unknown
- 2006-08-18 SI SI200632332T patent/SI2347762T1/sl unknown
- 2006-08-18 PL PL10016112T patent/PL2347762T3/pl unknown
- 2006-08-18 ES ES10016112T patent/ES2736184T3/es active Active
-
2008
- 2008-02-19 IL IL189607A patent/IL189607A/en active IP Right Grant
-
2011
- 2011-02-16 AU AU2011200663A patent/AU2011200663B2/en active Active
- 2011-04-12 US US13/084,757 patent/US8329648B2/en active Active
-
2012
- 2012-12-07 US US13/708,474 patent/US8906851B2/en active Active
-
2014
- 2014-10-15 JP JP2014210957A patent/JP5980872B2/ja active Active
- 2014-11-25 US US14/553,549 patent/US20150150948A1/en not_active Abandoned
-
2015
- 2015-12-27 IL IL243317A patent/IL243317A0/en unknown
-
2016
- 2016-05-31 US US15/168,350 patent/US9884092B2/en active Active
-
2018
- 2018-02-05 US US15/888,519 patent/US20180333468A1/en not_active Abandoned
-
2019
- 2019-06-04 CY CY20191100588T patent/CY1122010T1/el unknown
-
2020
- 2020-01-24 US US16/752,386 patent/US20200222509A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008110504A (ru) | Способы лечения диабета и снижения массы тела | |
| Holst et al. | Glucagon-like peptide-1, glucose homeostasis and diabetes | |
| Mannucci et al. | Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus | |
| Liu et al. | Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years | |
| Medved et al. | N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans | |
| Dioguardi | To give or not to give? Lessons from the arginine paradox | |
| Thondam et al. | Effects of chronic treatment with metformin on dipeptidyl peptidase‐4 activity, glucagon‐like peptide 1 and ghrelin in obese patients with type 2 diabetes mellitus | |
| EA200870575A1 (ru) | Композиции и способы лечения застойной сердечной недостаточности | |
| Andreasen et al. | Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy | |
| Ranganath | Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 | |
| Fujioka | Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction | |
| Washizawa et al. | Comparative effects of glucagon‐like peptide‐2 (GLP‐2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats | |
| AR074990A1 (es) | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina | |
| CY1106971T1 (el) | Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης | |
| EP2594565A3 (en) | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | |
| UA87009C2 (ru) | Композиции, которые содержат гибридные белки-аналоги glp-1 | |
| RU2005131832A (ru) | Композиция для введения железа при лечении синдрома беспокойных ног | |
| IL146868A0 (en) | A pharmaceutical composition containing an igf-i/igfbp-3 complex | |
| Park et al. | Changes in orexin-A and neuropeptide Y expression in the hypothalamus of the fasted and high-fat diet fed rats | |
| Qiu et al. | Long‐Lasting Designer Insulin with Glucose‐Dependent Solubility Markedly Reduces Risk of Hypoglycemia | |
| Salehi et al. | Differential effect of gastric bypass versus sleeve gastrectomy on insulinotropic action of endogenous incretins | |
| Munir et al. | Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes | |
| Tobe et al. | Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline | |
| Zisman et al. | Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease | |
| Hansen et al. | Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20140327 |